Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2018

12.01.2018 | Urologic Oncology

Dialysis Increases the Risk of Bladder Recurrence in Patients with Upper Tract Urothelial Cancer: A Population-Based Study

verfasst von: Ming-Yen Lin, MHA, PhD, Wei-Ming Li, MD, PhD, Chun-Nung Huang, MD, PhD, Huei-Lan Lee, MDS, Sheng-Wen Niu, MD, Li-Tzong Chen, MD, PhD, Wen-Jeng Wu, MD, PhD, Shang-Jyh Hwang, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The relation of dialysis to tumor recurrence in patients with upper tract urothelial cancer (UTUC) is unknown; however, a limited number of small-scale studies suggest that patients with renal diseases prior to UTUC are more likely to exhibit bladder recurrence. We performed a population-based analysis to determine the effect of dialysis on bladder recurrence for patients with UTUC.

Methods

This retrospective cohort study included patients diagnosed with UTUC (2002–2007) from the Taiwan National Cancer Registry and divided them into two groups—dialysis and non-dialysis groups. These patients were followed up until bladder recurrence, death, or the end of 2010. Competing risk analyses adjusting covariates and death were applied to determine the relation of dialysis and bladder recurrence.

Results

Of the 5141 eligible patients, 548 (10.7%) were undergoing dialysis. The cumulative bladder recurrence was significantly higher in the dialysis group than in the non-dialysis group (29% vs. 21%, modified log-rank p < 0.001). In the multivariable analysis, the dialysis group exhibited a 64% increased bladder recurrence risk (cause-specific hazard ratio 1.64, 95% confidence interval 1.34–2.01, p < 0.001), which was confirmed using stratification and propensity score weighting methods. The other prognostic factors for bladder recurrence were sex, diabetes, cardiac disorder, Charlson Comorbidity Index, and tumor grade.

Conclusions

Despite unknown reasons, approximately one-tenth of patients with UTUC have experienced dialysis treatment. Patients undergoing dialysis have a higher risk of bladder recurrence. Various treatment and screening strategies should be developed for dialysis and non-dialysis patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. 2011;107(7):1059–64.CrossRefPubMed Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. 2011;107(7):1059–64.CrossRefPubMed
2.
Zurück zum Zitat Matin SF, Shariat SF, Milowsky MI, et al. Highlights from the first symposium on upper tract urothelial carcinoma. Paper presented at Urologic Oncology: Seminars and Original Investigations 2014. Matin SF, Shariat SF, Milowsky MI, et al. Highlights from the first symposium on upper tract urothelial carcinoma. Paper presented at Urologic Oncology: Seminars and Original Investigations 2014.
3.
Zurück zum Zitat Fradet V, Mauermann J, Kassouf W, et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. Urol Oncol. 2014;32(6):839–45.CrossRefPubMed Fradet V, Mauermann J, Kassouf W, et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. Urol Oncol. 2014;32(6):839–45.CrossRefPubMed
4.
Zurück zum Zitat Li CC, Chang TH, Wu WJ, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54(5):1127–35.CrossRefPubMed Li CC, Chang TH, Wu WJ, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54(5):1127–35.CrossRefPubMed
5.
6.
Zurück zum Zitat Takaoka Ei, Hinotsu S, Joraku A, et al. Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int J Urol. 2010;17(7):623–28.CrossRef Takaoka Ei, Hinotsu S, Joraku A, et al. Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int J Urol. 2010;17(7):623–28.CrossRef
7.
Zurück zum Zitat Fang D, Zhang L, Li X, et al. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center. J Cancer Res Clin Oncol. 2014;140(3):477–85.CrossRefPubMed Fang D, Zhang L, Li X, et al. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center. J Cancer Res Clin Oncol. 2014;140(3):477–85.CrossRefPubMed
8.
Zurück zum Zitat Remzi M, Shariat S, Huebner W, Fajkovic H, Seitz C. Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? Ther Adv Urol. 2011;3(2):69–80.CrossRefPubMedPubMedCentral Remzi M, Shariat S, Huebner W, Fajkovic H, Seitz C. Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? Ther Adv Urol. 2011;3(2):69–80.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Abouassaly R, Alibhai SM, Shah N, Timilshina N, Fleshner N, Finelli A. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology. 2010;76(4):895–901.CrossRefPubMed Abouassaly R, Alibhai SM, Shah N, Timilshina N, Fleshner N, Finelli A. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology. 2010;76(4):895–901.CrossRefPubMed
10.
Zurück zum Zitat Jeldres C, Sun M, Isbarn H, et al. A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology. 2010;75(2):315–20.CrossRefPubMed Jeldres C, Sun M, Isbarn H, et al. A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology. 2010;75(2):315–20.CrossRefPubMed
11.
Zurück zum Zitat Rouprêt M, Babjuk M, Compérat E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013;63(6):1059–71.CrossRefPubMed Rouprêt M, Babjuk M, Compérat E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013;63(6):1059–71.CrossRefPubMed
12.
Zurück zum Zitat Seisen T, Granger B, Colin P, et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol. 2015;67(6):1122–33.CrossRefPubMed Seisen T, Granger B, Colin P, et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol. 2015;67(6):1122–33.CrossRefPubMed
13.
Zurück zum Zitat Leow JJ, Orsola A, Chang SL, Bellmunt J. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev. 2015;41(4):310–19.CrossRefPubMed Leow JJ, Orsola A, Chang SL, Bellmunt J. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev. 2015;41(4):310–19.CrossRefPubMed
14.
Zurück zum Zitat Hirano D, Okada Y, Nagane Y, et al. Intravesical recurrence after surgical management of urothelial carcinoma of the upper urinary tract. Urol Int. 2012;89(1):71–7.CrossRefPubMed Hirano D, Okada Y, Nagane Y, et al. Intravesical recurrence after surgical management of urothelial carcinoma of the upper urinary tract. Urol Int. 2012;89(1):71–7.CrossRefPubMed
15.
Zurück zum Zitat Li WM, Li CC, Ke HL, Wu WJ, Huang CN, Huang CH. The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy. J Urol. 2009;182(2):451–58.CrossRefPubMed Li WM, Li CC, Ke HL, Wu WJ, Huang CN, Huang CH. The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy. J Urol. 2009;182(2):451–58.CrossRefPubMed
16.
Zurück zum Zitat Chung SD, Huang KH, Lai MK, et al. CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Am J Kidney Dis. 2007;50(5):743–53.CrossRefPubMed Chung SD, Huang KH, Lai MK, et al. CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Am J Kidney Dis. 2007;50(5):743–53.CrossRefPubMed
17.
Zurück zum Zitat Wang TY, Hu CJ, Kuo CW, et al. High incidence and recurrence of transitional cell carcinoma in Taiwanese patients with end-stage renal disease. Nephrology. 2011;16(2):225–31.CrossRefPubMed Wang TY, Hu CJ, Kuo CW, et al. High incidence and recurrence of transitional cell carcinoma in Taiwanese patients with end-stage renal disease. Nephrology. 2011;16(2):225–31.CrossRefPubMed
18.
Zurück zum Zitat Chung SD, Huang KH, Lai MK, et al. CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Am J Kidney Dis. 2007;50(5):743–53.CrossRefPubMed Chung SD, Huang KH, Lai MK, et al. CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Am J Kidney Dis. 2007;50(5):743–53.CrossRefPubMed
19.
Zurück zum Zitat Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–19.CrossRefPubMed Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–19.CrossRefPubMed
20.
Zurück zum Zitat Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988:1141–54. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988:1141–54.
21.
Zurück zum Zitat Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transpl 2013; 28(11): 2670–77.CrossRef Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transpl 2013; 28(11): 2670–77.CrossRef
22.
Zurück zum Zitat Wang LJ, Lee SY, Teh BT, Chuang CK, Nortier J. Upper tract urothelial carcinomas in patients with chronic kidney disease: relationship with diagnostic challenge. BioMed Res Int. 2014;2014:989458.PubMedPubMedCentral Wang LJ, Lee SY, Teh BT, Chuang CK, Nortier J. Upper tract urothelial carcinomas in patients with chronic kidney disease: relationship with diagnostic challenge. BioMed Res Int. 2014;2014:989458.PubMedPubMedCentral
23.
Zurück zum Zitat Tanaka N, Miyajima A, Kikuchi E, et al. Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma. Br J Cancer. 2012;106(2):290–96.CrossRefPubMed Tanaka N, Miyajima A, Kikuchi E, et al. Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma. Br J Cancer. 2012;106(2):290–96.CrossRefPubMed
24.
Zurück zum Zitat Debelle FD, Vanherweghem J-L, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74(2):158–69.CrossRefPubMed Debelle FD, Vanherweghem J-L, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74(2):158–69.CrossRefPubMed
25.
Zurück zum Zitat Poon SL, Pang S-T, McPherson JR, et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med. 2013;5(197):197ra101. Poon SL, Pang S-T, McPherson JR, et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med. 2013;5(197):197ra101.
26.
Zurück zum Zitat Chen CH, Dickman KG, Huang CY, et al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer. 2013;133(1):14–20.CrossRefPubMed Chen CH, Dickman KG, Huang CY, et al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer. 2013;133(1):14–20.CrossRefPubMed
27.
Zurück zum Zitat Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved. Am J Nephrol. 1998;18(2):89–95.CrossRefPubMed Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved. Am J Nephrol. 1998;18(2):89–95.CrossRefPubMed
28.
29.
Zurück zum Zitat Balkwill F. TNF-α in promotion and progression of cancer. Cancer Meta Rev. 2006;25(3):409–16.CrossRefPubMed Balkwill F. TNF-α in promotion and progression of cancer. Cancer Meta Rev. 2006;25(3):409–16.CrossRefPubMed
30.
Zurück zum Zitat Ito A, Bebo BF, Matejuk A, et al. Estrogen treatment down-regulates TNF-α production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J Immunol. 2001;167(1):542–52.CrossRefPubMed Ito A, Bebo BF, Matejuk A, et al. Estrogen treatment down-regulates TNF-α production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J Immunol. 2001;167(1):542–52.CrossRefPubMed
Metadaten
Titel
Dialysis Increases the Risk of Bladder Recurrence in Patients with Upper Tract Urothelial Cancer: A Population-Based Study
verfasst von
Ming-Yen Lin, MHA, PhD
Wei-Ming Li, MD, PhD
Chun-Nung Huang, MD, PhD
Huei-Lan Lee, MDS
Sheng-Wen Niu, MD
Li-Tzong Chen, MD, PhD
Wen-Jeng Wu, MD, PhD
Shang-Jyh Hwang, MD
Publikationsdatum
12.01.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6295-3

Weitere Artikel der Ausgabe 4/2018

Annals of Surgical Oncology 4/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.